- About Us
- Nano-Social Network
- Nano Consulting
- My Account
BioForce Nanosciences, Inc., a wholly-owned subsidiary of BioForce Nanosciences Holdings, Inc. (OTCBB:BFNH), today announced that it has received notice from the U.S. Patent and Trademark Office (USPTO) that its "Protein Nanoarray" patent (US Pat. No. 6,573,369) has been upheld following a request for re-examination of the previously issued patent by a third party.
BioForce currently commercializes ultramicro arrays that are created using its Nano eNabler(tm) system. These miniaturized diagnostic and discovery tests have features sizes in the one micrometer to twenty micrometer diameter range (a human hair is about 70 micrometers in diameter). The Protein Nanoarray patent covers arrays of proteins having feature sizes of less than one micron squared and containing one or more different protein species. This size scale represents the ultimate level of miniaturization for biological diagnostic and discovery tests.
"This patent has now undergone extraordinary analysis by the USPTO" explained Dr. Eric Henderson, BioForce's founder, CEO and co-inventor of the patent. "Our success in this reexamination gives us confidence that as we make progress toward commercial development of miniaturized diagnostic tests we will have the appropriate intellectual property protection. We have created prototype Protein Nanoarrays as described in this patent and are positioned to begin to commercialize them when the market is ready."
Curtis Mosher, BioForce's Vice President of R&D and co-inventor of the patent, stated, "We continue to make improvements in our Nano eNabler (tm) system that allow it to create extremely miniaturized diagnostics tests. With tests this small a single drop of blood, a tear, or a few cells from a cheek swab can be used for multiple diagnoses with minimal patient impact. This is a fundamental requirement for our long term business goal of patient empowerment and truly personalized medicine."
About BioForce Nanosciences, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization; patterning and cell adhesion; and printing proteins to guide neural cell growth. For more information, visit http://www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in the Company's most recent filings with the Securities and Exchange Commission. The Company's actual results could differ materially from such forward-looking statements. We assume no duty to update these statements at any future date.
For more information, please click here
RedChip Companies Inc.
1-800-REDCHIP (733-2447) ext 104
BioForce Nanosciences Holdings, Inc.
Greg Brown, CFO
515 233 8333 x118
Copyright © PrimeNewswireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017
Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Intertronics introduce new nanoparticle deagglomeration technology March 15th, 2017